Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer

Christopher G. Bazewicz, Saketh S. Dinavahi, Todd Schell, Gavin Robertson

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The role of aldehyde dehydrogenase (ALDH) in carcinogenesis and resistance to cancer therapies is well known. Mounting evidence also suggests a potentially important role for ALDH in the induction and function of regulatory T (Treg) cells. Treg cells are important cells of the immune system involved in promoting immune tolerance and preventing aberrant immune responses to beneficial or non-harmful antigens. However, Treg cells also impair tumor immunity, leading to the progression of various carcinomas. ALDH expression and the subsequent production of retinoic acid by numerous cells, including dendritic cells, macrophages, eosinophils and epithelial cells, seems important in Treg induction and function in multiple organ systems. This is particularly evident in the gastrointestinal tract, pulmonary tract and skin, which are exposed to a myriad of environmental antigens and represent interfaces between the human body and the outside world. Expression of ALDH in Treg cells themselves may also be involved in the proliferation of these cells and resistance to certain cytotoxic therapies. Hence, inhibition of ALDH expression may be useful to treat cancer. Besides the direct effect of ALDH inhibition on carcinogenesis and resistance to cancer therapies, inhibition of ALDH could potentially augment the immune response to tumor antigens by inhibiting Treg induction, function and ability to promote immune tolerance to tumor cells in multiple cancer types.

Original languageEnglish (US)
Pages (from-to)47-55
Number of pages9
JournalImmunology
Volume156
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Aldehyde Dehydrogenase
Regulatory T-Lymphocytes
Immunity
Neoplasms
Immune Tolerance
Carcinogenesis
Antigens
Neoplasm Antigens
Tretinoin
Human Body
Eosinophils
Dendritic Cells
Gastrointestinal Tract
Immune System
Therapeutics
Epithelial Cells
Macrophages
Cell Proliferation
Carcinoma
Lung

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Bazewicz, Christopher G. ; Dinavahi, Saketh S. ; Schell, Todd ; Robertson, Gavin. / Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer. In: Immunology. 2019 ; Vol. 156, No. 1. pp. 47-55.
@article{75d72ff0e52948d299c7b0f3d71449fa,
title = "Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer",
abstract = "The role of aldehyde dehydrogenase (ALDH) in carcinogenesis and resistance to cancer therapies is well known. Mounting evidence also suggests a potentially important role for ALDH in the induction and function of regulatory T (Treg) cells. Treg cells are important cells of the immune system involved in promoting immune tolerance and preventing aberrant immune responses to beneficial or non-harmful antigens. However, Treg cells also impair tumor immunity, leading to the progression of various carcinomas. ALDH expression and the subsequent production of retinoic acid by numerous cells, including dendritic cells, macrophages, eosinophils and epithelial cells, seems important in Treg induction and function in multiple organ systems. This is particularly evident in the gastrointestinal tract, pulmonary tract and skin, which are exposed to a myriad of environmental antigens and represent interfaces between the human body and the outside world. Expression of ALDH in Treg cells themselves may also be involved in the proliferation of these cells and resistance to certain cytotoxic therapies. Hence, inhibition of ALDH expression may be useful to treat cancer. Besides the direct effect of ALDH inhibition on carcinogenesis and resistance to cancer therapies, inhibition of ALDH could potentially augment the immune response to tumor antigens by inhibiting Treg induction, function and ability to promote immune tolerance to tumor cells in multiple cancer types.",
author = "Bazewicz, {Christopher G.} and Dinavahi, {Saketh S.} and Todd Schell and Gavin Robertson",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/imm.13016",
language = "English (US)",
volume = "156",
pages = "47--55",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "1",

}

Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer. / Bazewicz, Christopher G.; Dinavahi, Saketh S.; Schell, Todd; Robertson, Gavin.

In: Immunology, Vol. 156, No. 1, 01.01.2019, p. 47-55.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancer

AU - Bazewicz, Christopher G.

AU - Dinavahi, Saketh S.

AU - Schell, Todd

AU - Robertson, Gavin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The role of aldehyde dehydrogenase (ALDH) in carcinogenesis and resistance to cancer therapies is well known. Mounting evidence also suggests a potentially important role for ALDH in the induction and function of regulatory T (Treg) cells. Treg cells are important cells of the immune system involved in promoting immune tolerance and preventing aberrant immune responses to beneficial or non-harmful antigens. However, Treg cells also impair tumor immunity, leading to the progression of various carcinomas. ALDH expression and the subsequent production of retinoic acid by numerous cells, including dendritic cells, macrophages, eosinophils and epithelial cells, seems important in Treg induction and function in multiple organ systems. This is particularly evident in the gastrointestinal tract, pulmonary tract and skin, which are exposed to a myriad of environmental antigens and represent interfaces between the human body and the outside world. Expression of ALDH in Treg cells themselves may also be involved in the proliferation of these cells and resistance to certain cytotoxic therapies. Hence, inhibition of ALDH expression may be useful to treat cancer. Besides the direct effect of ALDH inhibition on carcinogenesis and resistance to cancer therapies, inhibition of ALDH could potentially augment the immune response to tumor antigens by inhibiting Treg induction, function and ability to promote immune tolerance to tumor cells in multiple cancer types.

AB - The role of aldehyde dehydrogenase (ALDH) in carcinogenesis and resistance to cancer therapies is well known. Mounting evidence also suggests a potentially important role for ALDH in the induction and function of regulatory T (Treg) cells. Treg cells are important cells of the immune system involved in promoting immune tolerance and preventing aberrant immune responses to beneficial or non-harmful antigens. However, Treg cells also impair tumor immunity, leading to the progression of various carcinomas. ALDH expression and the subsequent production of retinoic acid by numerous cells, including dendritic cells, macrophages, eosinophils and epithelial cells, seems important in Treg induction and function in multiple organ systems. This is particularly evident in the gastrointestinal tract, pulmonary tract and skin, which are exposed to a myriad of environmental antigens and represent interfaces between the human body and the outside world. Expression of ALDH in Treg cells themselves may also be involved in the proliferation of these cells and resistance to certain cytotoxic therapies. Hence, inhibition of ALDH expression may be useful to treat cancer. Besides the direct effect of ALDH inhibition on carcinogenesis and resistance to cancer therapies, inhibition of ALDH could potentially augment the immune response to tumor antigens by inhibiting Treg induction, function and ability to promote immune tolerance to tumor cells in multiple cancer types.

UR - http://www.scopus.com/inward/record.url?scp=85056873726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056873726&partnerID=8YFLogxK

U2 - 10.1111/imm.13016

DO - 10.1111/imm.13016

M3 - Review article

VL - 156

SP - 47

EP - 55

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 1

ER -